Heart disease drug gets extended testing in 700 patients
NCT ID NCT06679946
Summary
This study continues testing vutrisiran, an investigational drug for hereditary heart amyloidosis, in patients who previously participated in related trials. Researchers want to understand the long-term safety and effectiveness of continued treatment. The study measures heart function, quality of life, and survival outcomes over extended treatment periods.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Phoenix, Arizona, 85054, United States
-
Clinical Trial Site
Beverly Hills, California, 90211, United States
-
Clinical Trial Site
La Jolla, California, 92037, United States
-
Clinical Trial Site
Stanford, California, 94305, United States
-
Clinical Trial Site
Washington D.C., District of Columbia, 20010, United States
-
Clinical Trial Site
Chicago, Illinois, 60637, United States
-
Clinical Trial Site
Glenview, Illinois, 60026, United States
-
Clinical Trial Site
Indianapolis, Indiana, 46202, United States
-
Clinical Trial Site
Kansas City, Kansas, 66160, United States
-
Clinical Trial Site
Baltimore, Maryland, 21287, United States
-
Clinical Trial Site
Boston, Massachusetts, 02115, United States
-
Clinical Trial Site
Boston, Massachusetts, 02118, United States
-
Clinical Trial Site
Rochester, Minnesota, 55905, United States
-
Clinical Trial Site
St Louis, Missouri, 63110, United States
-
Clinical Trial Site
Omaha, Nebraska, 68198, United States
-
Clinical Trial Site
New York, New York, 10029, United States
-
Clinical Trial Site
New York, New York, 10032, United States
-
Clinical Trial Site
Durham, North Carolina, 27710, United States
-
Clinical Trial Site
Cleveland, Ohio, 44195, United States
-
Clinical Trial Site
Columbus, Ohio, 43214, United States
-
Clinical Trial Site
Philadelphia, Pennsylvania, 19104, United States
-
Clinical Trial Site
Nashville, Tennessee, 37232, United States
-
Clinical Trial Site
Dallas, Texas, 75246, United States
-
Clinical Trial Site
Salt Lake City, Utah, 84132, United States
-
Clinical Trial Site
Buenos Aires, C1093AAS, Argentina
-
Clinical Trial Site
Buenos Aires, C1199ABB, Argentina
-
Clinical Trial Site
Buenos Aires, C1428, Argentina
-
Clinical Trial Site
Córdoba, X5000KEH, Argentina
-
Clinical Trial Site
Rosario, S2000DEJ, Argentina
-
Clinical Trial Site
Rosario, S2000DSR, Argentina
-
Clinical Trial Site
Rosario, S2000PBJ, Argentina
-
Clinical Trial Site
Vienna, 1090, Austria
-
Clinical Trial Site
Vienna, 1210, Austria
-
Clinical Trial Site
Aalst, 9300, Belgium
-
Clinical Trial Site
Anderlecht, 1070, Belgium
-
Clinical Trial Site
Dendermonde, 9200, Belgium
-
Clinical Trial Site
Ghent, 9000, Belgium
-
Clinical Trial Site
Hasselt, 3500, Belgium
-
Clinical Trial Site
Leuven, 3000, Belgium
-
Clinical Trial Site
Liège, 4000, Belgium
-
Clinical Trial Site
Roeselare, 8800, Belgium
-
Clinical Trial Site
Ribeirão Preto, 14026-900, Brazil
-
Clinical Trial Site
Ribeirão Preto, 14051-140, Brazil
-
Clinical Trial Site
Rio de Janeiro, 22280-020, Brazil
-
Clinical Trial Site
São Paulo, 04012-180, Brazil
-
Clinical Trial Site
São Paulo, 05403-000, Brazil
-
Clinical Trial Site
Prague, 120 00, Czechia
-
Clinical Trial Site
Prague, 128 21, Czechia
-
Clinical Trial Site
Prague, 140 21, Czechia
-
Clinical Trial Site
Aarhus N, 8200, Denmark
-
Clinical Trial Site
København Ø, 2100, Denmark
-
Clinical Trial Site
Odense C, 5000, Denmark
-
Clinical Trial Site
Créteil, 94000, France
-
Clinical Trial Site
Marseille, 13005, France
-
Clinical Trial Site
Paris, 75018, France
-
Clinical Trial Site
Rennes, 35000, France
-
Clinical Trial Site
Toulouse, 31059, France
-
Clinical Trial Site
Bologna, 40138, Italy
-
Clinical Trial Site
Florence, 50134, Italy
-
Clinical Trial Site
Pavia, 27100, Italy
-
Clinical Trial Site
Groningen, 9713 GZ, Netherlands
-
Clinical Trial Site
Maastricht, 6229 HX, Netherlands
-
Clinical Trial Site
Utrecht, 3584 CX, Netherlands
-
Clinical Trial Site
Oslo, 372, Norway
-
Clinical Trial Site
Creixomil, 4835-044, Portugal
-
Clinical Trial Site
Lisbon, 1649-035, Portugal
-
Clinical Trial Site
Porto, 4099-001, Portugal
-
Clinical Trial Site
Viseu, 3504-509, Portugal
-
Clinical Trial Site
Seoul, 03080, South Korea
-
Clinical Trial Site
Seoul, 03722, South Korea
-
Clinical Trial Site
Seoul, 06351, South Korea
-
Clinical Trial Site
Barcelona, 08035, Spain
-
Clinical Trial Site
Bilbao, 48013, Spain
-
Clinical Trial Site
L'Hospitalet de Llobregat, 8907, Spain
-
Clinical Trial Site
Madrid, 28222, Spain
-
Clinical Trial Site
Málaga, 29010, Spain
-
Clinical Trial Site
Gothenburg, 413 45, Sweden
-
Clinical Trial Site
Solna, 171 76, Sweden
-
Clinical Trial Site
Umeå, 907 37, Sweden
-
Clinical Trial Site
Taipei, 112, Taiwan
-
Clinical Trial Site
Bellshill, ML4 3NJ, United Kingdom
-
Clinical Trial Site
Birmingham, B15 2SQ, United Kingdom
-
Clinical Trial Site
Cardiff, CF15 9SS, United Kingdom
-
Clinical Trial Site
Hexham, NE46 1QJ, United Kingdom
-
Clinical Trial Site
London, NW3 2QG, United Kingdom
-
Clinical Trial Site
London, SE1 1YR, United Kingdom
-
Clinical Trial Site
Manchester, M15 6SE, United Kingdom
Conditions
Explore the condition pages connected to this study.